A137310 Stock Overview
SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||₩45,850.00|
|52 Week High||₩81,000.00|
|52 Week Low||₩40,400.00|
|1 Month Change||-13.98%|
|3 Month Change||-26.87%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-24.84%|
Recent News & Updates
|A137310||KR Medical Equipment||KR Market|
Return vs Industry: Insufficient data to determine how A137310 performed against the KR Medical Equipment industry.
Return vs Market: Insufficient data to determine how A137310 performed against the KR Market.
|A137310 Average Weekly Movement||5.7%|
|Medical Equipment Industry Average Movement||5.6%|
|Market Average Movement||5.5%|
|10% most volatile stocks in KR Market||10.6%|
|10% least volatile stocks in KR Market||3.2%|
Stable Share Price: A137310 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: A137310's weekly volatility (6%) has been stable over the past year.
About the Company
|2010||326||Hyo Keun Lee||https://www.sdbiosensor.com|
SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company’s products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters.
SD BioSensor Fundamentals Summary
|A137310 fundamental statistics|
Is A137310 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A137310 income statement (TTM)|
|Cost of Revenue||₩1.36t|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||10.53k|
|Net Profit Margin||36.34%|
How did A137310 perform over the long term?See historical performance and comparison
2.8%Current Dividend Yield
Is SD BioSensor undervalued compared to its fair value and its price relative to the market?
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: A137310 (₩45850) is trading below our estimate of fair value (₩59900.65)
Significantly Below Fair Value: A137310 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: A137310 is good value based on its PE Ratio (4.4x) compared to the KR Medical Equipment industry average (13x).
PE vs Market: A137310 is good value based on its PE Ratio (4.4x) compared to the KR market (14.7x).
Price to Earnings Growth Ratio
PEG Ratio: A137310's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: A137310 is good value based on its PB Ratio (2.1x) compared to the KR Medical Equipment industry average (2.6x).
How is SD BioSensor forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A137310's earnings are forecast to decline over the next 3 years (-37.7% per year).
Earnings vs Market: A137310's earnings are forecast to decline over the next 3 years (-37.7% per year).
High Growth Earnings: A137310's earnings are forecast to decline over the next 3 years.
Revenue vs Market: A137310's revenue is expected to decline over the next 3 years (-28.3% per year).
High Growth Revenue: A137310's revenue is forecast to decline over the next 3 years (-28.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A137310's Return on Equity is forecast to be low in 3 years time (10.4%).
How has SD BioSensor performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical Healthcare annual earnings growth
Earnings and Revenue History
Quality Earnings: A137310 has high quality earnings.
Growing Profit Margin: Insufficient data to determine if A137310's profit margins have improved over the past year.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A137310's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A137310's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: Insufficient data to determine if A137310's earnings growth over the past year exceeded the Medical Equipment industry average.
Return on Equity
High ROE: A137310's Return on Equity (48.3%) is considered outstanding.
How is SD BioSensor's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: A137310's short term assets (₩2,578.0B) exceed its short term liabilities (₩779.9B).
Long Term Liabilities: A137310's short term assets (₩2,578.0B) exceed its long term liabilities (₩21.9B).
Debt to Equity History and Analysis
Debt Level: A137310 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A137310's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: A137310's debt is well covered by operating cash flow (722.3%).
Interest Coverage: A137310 earns more interest than it pays, so coverage of interest payments is not a concern.
What is SD BioSensor current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: A137310's dividend (2.76%) is higher than the bottom 25% of dividend payers in the KR market (0.83%).
High Dividend: A137310's dividend (2.76%) is in the top 25% of dividend payers in the KR market (2.69%)
Stability and Growth of Payments
Stable Dividend: Too early to tell whether A137310's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if A137310's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (11.6%), A137310's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (12.3%), A137310's dividend payments are thoroughly covered by cash flows.
How experienced are the management team and are they aligned to shareholders interests?
Hyo Keun Lee
Hyo Keun Lee is Vice Chairman and Chief Executive Officer of SD BioSensor, Inc.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: A137310 only recently listed within the past 12 months.
SD BioSensor, Inc's employee growth, exchange listings and data sources
- Name: SD BioSensor, Inc
- Ticker: A137310
- Exchange: KOSE
- Founded: 2010
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: ₩4.637t
- Shares outstanding: 101.14m
- Website: https://www.sdbiosensor.com
Number of Employees
- SD BioSensor, Inc
- 16 Deokyeong-daero
- 4th and 5th Floors
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/09 00:00|
|End of Day Share Price||2022/05/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.